Ar­row­head shelves one car­diometa­bol­ic drug can­di­date, fo­cus­es on an­oth­er

On Tues­day, Ar­row­head Phar­ma­ceu­ti­cals said it will shift fo­cus to its ex­per­i­men­tal car­diometa­bol­ic drug ploza­sir­an and will de­pri­or­i­tize its work on zo­dasir­an, em­pha­siz­ing the need …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER